Please login to the form below

Not currently logged in
Email:
Password:

aTyr appoints rare disease expert as president

Frederic Chereau has senior experience at Shire and Genzyme

US-based firm aTyr Pharma has appointed Frederic Chereau as president and chief operating officer to support the advance of its portfolio of medicines for rare diseases.

Chereau has significant experience in the field, working at rare disease specialist Genzyme from 1999 to 2008, eventually becoming president and general manager of the company's cardiovascular business.

He was later president and CEO of Pervasis Therapeutics, which was acquired by Shire in 2012.

Dr John Mendlein, CEO and executive chairman of aTyr Pharma, said that Chereau's appointment will guide the company's “global outreach and strategic partnerships”.

7th February 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics